clarithromycin 500mg tablets
milpharm ltd - clarithromycin - oral tablet - 500mg
apo-clarithromycin
apotex nz ltd - clarithromycin 250mg; clarithromycin 250mg - film coated tablet - 250 mg - active: clarithromycin 250mg excipient: colloidal silicon dioxide croscarmellose sodium hypromellose iron oxide yellow macrogol 8000 magnesium stearate microcrystalline cellulose titanium dioxide active: clarithromycin 250mg excipient: colloidal silicon dioxide croscarmellose sodium hypromellose iron oxide yellow macrogol 8000 magnesium stearate microcrystalline cellulose titanium dioxide - clarithromycin is indicated for treatment of infections caused by susceptible organisms. such infections include: 1. respiratory tract infections including bronchitis, pneumonia, tonsillitis, sinusitis and pharyngitis. 2. skin and soft tissue infections such as folliculitis, cellulitis and erysipelas. 3. disseminated or localized mycobacterial infections due to mycobacterium avium or mycobacterium intracellulare. localized infections due to mycobacterium chelonae, mycobacterium fortuitum or mycobacterium kansasii. 4. prevention of disseminated mycobacterium avium complex infection in hiv-infected patients with cd4 lymphocyte counts less than or equal to 100/mm3.
clarithromycin tablet, film coated
teva pharmaceuticals usa, inc. - clarithromycin (unii: h1250jik0a) (clarithromycin - unii:h1250jik0a) - clarithromycin 250 mg - clarithromycin tablets usp are indicated for the treatment of mild to moderate infections caused by susceptible isolates of the designated bacteria in the conditions as listed below: pharyngitis/tonsillitis due to streptococcus pyogenes (the usual drug of choice in the treatment and prevention of streptococcal infections and the prophylaxis of rheumatic fever is penicillin administered by either the intramuscular or the oral route. clarithromycin is generally effective in the eradication of s. pyogenes from the nasopharynx; however, data establishing the efficacy of clarithromycin in the subsequent prevention of rheumatic fever are not available at present). acute maxillary sinusitis due to haemophilus influenzae , moraxella catarrhalis , or streptococcus pneumoniae . acute bacterial exacerbation of chronic bronchitis due to haemophilus influenzae , haemophilus parainfluenzae , moraxella catarrhalis , or streptococcus pneumoniae . community-acquired pneumonia due to haemophilus influenzae , mycoplasma pneum
clarithromycin- clarithromycin tablet, film coated
lake erie medical dba quality care products llc - clarithromycin (unii: h1250jik0a) (clarithromycin - unii:h1250jik0a) - clarithromycin 500 mg - clarithromycin tablets, usp are indicated in adults for the treatment of mild to moderate infections caused by susceptible isolates due to haemophilus influenzae , haemophilus parainfluenzae , moraxella catarrhalis , or streptococcus pneumoniae [see indications and usage (1.9)] . clarithromycin tablets, usp are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to haemophilus influenzae , moraxella catarrhalis , or streptococcus pneumoniae [see indications and usage (1.9)] . clarithromycin tablets, usp are indicated [see indications and usage (1.9)] for the treatment of mild to moderate infections caused by susceptible isolates due to: - haemophilus influenzae (in adults) - mycoplasma pneumoniae , streptococcus pneumoniae , chlamydophila pneumoniae clarithromycin tablets, usp are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to streptococcus pyogenes as an alternative in individuals who cannot use first line ther
clarithromycin tablet, film coated
lannett company, inc. - clarithromycin (unii: h1250jik0a) (clarithromycin - unii:h1250jik0a) - clarithromycin 250 mg - clarithromycin tablets, usp are indicated in adults for the treatment of mild to moderate infections caused by susceptible isolates due to haemophilus influenzae , haemophilus parainfluenzae , moraxella catarrhalis , or streptococcus pneumoniae [see indications and usage (1.9)] . clarithromycin tablets, usp are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to haemophilus influenzae , moraxella catarrhalis , or streptococcus pneumoniae [see indications and usage (1.9)] . clarithromycin tablets, usp are indicated [see indications and usage (1.9)] for the treatment of mild to moderate infections caused by susceptible isolates due to: - haemophilus influenzae (in adults) - mycoplasma pneumoniae , streptococcus pneumoniae , chlamydophila pneumoniae clarithromycin tablets, usp are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to streptococ
clarithromycin tablet, coated
west-ward pharmaceuticals corp. - clarithromycin (unii: h1250jik0a) (clarithromycin - unii:h1250jik0a) - clarithromycin 250 mg - clarithromycin is indicated in adults for the treatment of mild to moderate infections caused by susceptible isolates due to haemophilus influenzae, haemophilus parainfluenzae, moraxella catarrhalis, or streptococcus pneumoniae [see indications and usage (1.9) ]. clarithromycin is indicated for the treatment of mild to moderate infections caused by susceptible isolates due to haemophilus influenzae, moraxella catarrhalis, or streptococcus pneumoniae [see indications and usage (1.9) ]. clarithromycin is indicated [see indications and usage (1.9) ] for the treatment of mild to moderate infections caused by susceptible isolates due to: clarithromycin is indicated for the treatment of mild to moderate infections caused by susceptible isolates due to streptococcus pyogenes as an alternative in individuals who cannot use first line therapy. clarithromycin is indicated for the treatment of mild to moderate infections caused by susceptible isolates due to staphylococcus aureus, or streptococcus pyogenes . clari
clarithromycin tablet, film coated
pd-rx pharmaceuticals, inc. - clarithromycin (unii: h1250jik0a) (clarithromycin - unii:h1250jik0a) - clarithromycin 500 mg - clarithromycin tablets, usp are indicated in adults for the treatment of mild to moderate infections caused by susceptible isolates due to haemophilus influenzae , haemophilus parainfluenzae , moraxella catarrhalis , or streptococcus pneumoniae [see indications and usage (1.9)] . clarithromycin tablets, usp are indicated for the treatment of mild to moderate infections c
clarithromycin tablet, coated
blenheim pharmacal, inc. - clarithromycin (unii: h1250jik0a) (clarithromycin - unii:h1250jik0a) - clarithromycin 500 mg - clarithromycin tablets, usp are indicated for the treatment of mild to moderate infections caused by susceptible isolates of the designated bacteria in the conditions as listed below: adults (clarithromycin tablets, usp) pharyngitis/tonsillitis due to streptococcus pyogenes (the usual drug of choice in the treatment and prevention of streptococcal infections and the prophylaxis of rheumatic fever is penicillin administered by either the intramuscular or the oral route. clarithromycin tablets, usp are generally effective in the eradication of s. pyogenes from the nasopharynx; however, data establishing the efficacy of clarithromycin tablets, usp in the subsequent prevention of rheumatic fever are not available at present.) acute maxillary sinusitis due to haemophilus influenzae, moraxella catarrhalis or streptococcus pneumoniae. acute bacterial exacerbation of chronic bronchitis due to haemophilus influenzae,haemophilus parainfluenzae, moraxella catarrhalis , or streptococcus pneumoniae. community-acquired
clarithromycin tablet, coated
bryant ranch prepack - clarithromycin (unii: h1250jik0a) (clarithromycin - unii:h1250jik0a) - clarithromycin 500 mg - clarithromycin tablets, usp are indicated for the treatment of mild to moderate infections caused by susceptible isolates of the designated bacteria in the conditions as listed below: pharyngitis/tonsillitis due to streptococcus pyogenes (the usual drug of choice in the treatment and prevention of streptococcal infections and the prophylaxis of rheumatic fever is penicillin administered by either the intramuscular or the oral route. clarithromycin tablets, usp are generally effective in the eradication of s. pyogenes from the nasopharynx; however, data establishing the efficacy of clarithromycin tablets, usp in the subsequent prevention of rheumatic fever are not available at present.) acute maxillary sinusitis due to haemophilus influenzae , moraxella catarrhalis or streptococcus pneumoniae . acute bacterial exacerbation of chronic bronchitis due to haemophilus influenzae , haemophilus parainfluenzae , moraxella catarrhalis , or streptococcus pneumoniae . community-acquired pneumonia due to haemophilus in
clarithromycin extended release- clarithromycin tablet, film coated, extended release
ranbaxy pharmaceuticals inc. - clarithromycin (unii: h1250jik0a) (clarithromycin - unii:h1250jik0a) - tablet, film coated, extended release - 1000 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of clarithromycin extended-release tablets and other antibacterial drugs, clarithromycin extended-release tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. the efficacy and safety of clarithromycin extended-release tablets in treating other infections for which other formulations of clarithromycin are approved have not been established. clarithromycin is contraindicated in patients with a known hypersensitivity to clarithromycin, erythromycin, or any of the macrolide antibiotics. concomitant administration of clarithromycin and any of the following drugs is contraindicated: cisapride, p